Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -4,65k | 110,60k | Vente | 23,77 | 105,69k | -4,22% |
| 2026-05-18 | Dr. Shehnaaz SulimanIndependent Director | -5,74k | 144,19k | Vente | 25,12 | 20,20k | -22,13% |
| 2026-05-05 | Dr. Eric CrombezChief Medical Officer & Exec. VP | -344,00 | 8,59k | Vente | 24,96 | 51,19k | -0,67% |
| 2026-05-01 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -4,68k | 116,61k | Vente | 24,90 | 110,34k | -4,07% |
| 2026-04-01 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -4,68k | 98,20k | Vente | 20,97 | 18,73k | -20,00% |
| 2026-03-06 | Ms. Karah Herdman ParschauerChief Legal Officer & Exec. VP of Corporate Affairs | -9,53k | 208,31k | Vente | 21,40 - 22,67 | 41,55k | -18,65% |
| 2026-03-02 | Mr. John Richard PinionChief Quality Operations Officer & Exec. VP of Translational Sciences | -10,03k | 228,66k | Vente | 22,80 | 84,76k | -10,58% |
| 2026-03-02 | Mr. Erik HarrisExec. VP & Chief Commercial Officer | -10,54k | 240,29k | Vente | 22,80 | 61,71k | -14,59% |
| 2026-03-02 | Dr. Emil D. KakkisFounder, President, CEO & Director | -54,40k | 1,24M | Vente | 22,80 | 2,75M | -1,94% |
| 2026-03-02 | Ms. Karah Herdman ParschauerChief Legal Officer & Exec. VP of Corporate Affairs | -8,14k | 185,48k | Vente | 22,80 | 51,08k | -13,74% |
| 2026-03-02 | Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer | -1,63k | 37,21k | Vente | 22,80 | 27,99k | -5,51% |
| 2026-03-02 | Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer | -148,00 | 3,46k | Sale to Issuer | 23,39 | 27,99k | -0,53% |
| 2026-03-02 | Dr. Eric CrombezChief Medical Officer & Exec. VP | -7,03k | 160,26k | Vente | 22,80 | 45,61k | -13,35% |
| 2026-03-02 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -10,04k | 227,54k | Vente | 22,40 - 22,80 | 23,41k | -30,02% |
| 2026-03-02 | Mr. Dennis Karl HuangChief Technical Operations Officer and Exec. VP of Gene Therapy Operations | -999,00 | 23,37k | Sale to Issuer | 23,39 | 99,46k | -0,99% |
| 2026-02-02 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -3,06k | 72,12k | Vente | 23,56 | 18,55k | -14,16% |
| 2026-01-02 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -3,15k | 71,95k | Vente | 22,84 | 21,61k | -12,72% |
| 2025-12-29 | Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer | -85,00 | 2,92k | Vente | 34,38 | 24,60k | -0,34% |
| 2025-12-10 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -3,08k | 112,09k | Vente | 36,38 | 24,76k | -11,07% |
| 2025-10-13 | Mr. Howard HornExec. VP of Corporate Strategy & CFO | -7,94k | 250,25k | Vente | 31,51 | 27,84k | -22,19% |
| 2025-09-18 | Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer | -64,00 | 1,87k | Vente | 29,17 | 24,14k | -0,26% |
| 2025-09-12 | Ms. Karah Herdman ParschauerChief Legal Officer & Exec. VP of Corporate Affairs | -2,45k | 76,37k | Vente | 31,17 | 30,93k | -7,34% |
| 2025-09-05 | Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer | -84,00 | 2,64k | Vente | 31,39 | 24,28k | -0,34% |
| 2025-06-20 | Dr. Corazon Dating SandersIndependent Director | -2,41k | 89,92k | Vente | 37,39 | 9,60k | -20,03% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
